Subtopic Deep Dive
BAP1 Tumor Suppressor in Mesothelioma
Research Guide
What is BAP1 Tumor Suppressor in Mesothelioma?
BAP1 tumor suppressor gene mutations, both germline and somatic, predispose individuals to malignant mesothelioma, particularly in asbestos-exposed populations, by disrupting deubiquitination and tumor suppression functions.
Germline BAP1 mutations were first linked to mesothelioma predisposition in Testa et al. (2011, Nature Genetics, 1060 citations), identifying families with high cancer incidence. Somatic BAP1 alterations occur frequently in sporadic cases, as shown by whole-exome sequencing in Guo et al. (2014, Cancer Research, 312 citations). Over 10 key papers since 2011 document BAP1's role in diagnosis and prognosis.
Why It Matters
Germline BAP1 testing identifies high-risk families for surveillance, enabling early mesothelioma detection in asbestos-exposed relatives (Testa et al., 2011). BAP1-mutated mesothelioma shows 7-fold better survival, guiding prognosis and therapy selection (Baumann et al., 2014). Immunohistochemical BAP1 loss distinguishes mesothelioma from reactive mesothelium, improving diagnostic accuracy (Cigognetti et al., 2015). These advances support targeted screening in occupational cohorts.
Key Research Challenges
Distinguishing germline vs somatic mutations
Sequencing sporadic mesothelioma often reveals BAP1 alterations, but germline testing requires family history and functional assays to differentiate (Testa et al., 2011). Clinical guidelines lack standardized protocols for mutation classification (Baas et al., 2015). This gap delays hereditary risk assessment.
Developing BAP1-targeted therapies
BAP1 loss drives asbestos-induced mesotheliomagenesis, but no approved inhibitors exist despite HDACi preclinical promise (Carbone et al., 2019). Synthetic lethality screens identify few hits due to BAP1's nuclear role (Sekido, 2013). Clinical translation stalls without phase II trials.
Validating BAP1 IHC for diagnosis
BAP1 immunohistochemistry shows high specificity for mesothelioma vs. reactive cells, but sensitivity varies across subtypes (Cigognetti et al., 2015). Multi-marker panels including BAP1 improve accuracy, yet standardization lags (Bibby et al., 2016). Inter-lab reproducibility remains unproven.
Essential Papers
Germline BAP1 mutations predispose to malignant mesothelioma
Joseph R. Testa, Mitchell Cheung, Jianming Pei et al. · 2011 · Nature Genetics · 1.1K citations
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
Michele Carbone, Prasad S. Adusumilli, H. Richard Alexander et al. · 2019 · CA A Cancer Journal for Clinicians · 443 citations
Abstract Mesothelioma affects mostly older individuals who have been occupationally exposed to asbestos. The global mesothelioma incidence and mortality rates are unknown, because data are not avai...
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Paul Baas, Dean A. Fennell, Keith M. Kerr et al. · 2015 · Annals of Oncology · 413 citations
Whole-Exome Sequencing Reveals Frequent Genetic Alterations in <i>BAP1</i> , <i>NF2</i> , <i>CDKN2A</i> , and <i>CUL1</i> in Malignant Pleural Mesothelioma
Guangwu Guo, Juliann Chmielecki, Chandra Goparaju et al. · 2014 · Cancer Research · 312 citations
Abstract Malignant pleural mesothelioma (MPM) is an aggressive neoplasm associated with asbestos exposure. Although previous studies based on candidate gene approaches have identified important com...
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment
Anna Bibby, Selina Tsim, Nikolaos I. Kanellakis et al. · 2016 · European Respiratory Review · 300 citations
Malignant pleural mesothelioma is an aggressive malignancy of the pleural surface, predominantly caused by prior asbestos exposure. There is a global epidemic of malignant pleural mesothelioma unde...
BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations
Marta Cigognetti, Silvia Lonardi, Simona Fisogni et al. · 2015 · Modern Pathology · 298 citations
ERS/EACTS statement on the management of malignant pleural effusions
Anna Bibby, Patrick Dorn, Ioannis Psallidas et al. · 2018 · European Respiratory Journal · 296 citations
Malignant pleural effusions (MPE) are a common pathology, treated by respiratory physicians and thoracic surgeons alike. In recent years, several well-designed randomised clinical trials have been ...
Reading Guide
Foundational Papers
Start with Testa et al. (2011) for germline discovery in families; follow with Guo et al. (2014) for somatic landscape via WES; Baumann et al. (2014) quantifies survival benefit.
Recent Advances
Carbone et al. (2019) reviews prevention/diagnosis advances; Cigognetti et al. (2015) establishes BAP1 IHC utility; Baas et al. (2015) integrates into ESMO guidelines.
Core Methods
Whole-exome sequencing (Guo 2014); immunohistochemistry for BAP1 loss (Cigognetti 2015); pedigree analysis and survival modeling (Testa 2011, Baumann 2014).
How PapersFlow Helps You Research BAP1 Tumor Suppressor in Mesothelioma
Discover & Search
Research Agent uses searchPapers('BAP1 germline mesothelioma') to retrieve Testa et al. (2011, 1060 citations), then citationGraph reveals 200+ forward citations including Baumann et al. (2014). exaSearch uncovers cohort studies on BAP1 surveillance, while findSimilarPapers expands to NF2 co-mutations from Guo et al. (2014).
Analyze & Verify
Analysis Agent applies readPaperContent on Testa et al. (2011) to extract mutation spectra, then verifyResponse(CoVe) cross-checks survival claims against Baumann et al. (2014). runPythonAnalysis processes citation networks with pandas for BAP1 paper clustering; GRADE grading scores Carbone et al. (2019) as high-evidence for diagnostic utility.
Synthesize & Write
Synthesis Agent detects gaps in BAP1 therapy trials via contradiction flagging across Carbone (2019) and Sekido (2013). Writing Agent uses latexEditText for review drafting, latexSyncCitations imports 10 BAP1 papers, and latexCompile generates figures. exportMermaid visualizes BAP1-asbestos-mutation pathway.
Use Cases
"Extract survival data from BAP1 germline mesothelioma papers and plot hazard ratios"
Research Agent → searchPapers → Analysis Agent → readPaperContent(Baumann 2014) → runPythonAnalysis(pandas survival curve, matplotlib plot) → researcher gets CSV-exported Kaplan-Meier plot with 7-fold HR statistic.
"Draft LaTeX review section on BAP1 diagnostic IHC in mesothelioma"
Synthesis Agent → gap detection → Writing Agent → latexEditText('BAP1 loss specificity 95%') → latexSyncCitations(5 papers) → latexCompile → researcher gets PDF section with auto-formatted Cigognetti et al. (2015) figure.
"Find GitHub repos analyzing BAP1 mutation datasets from mesothelioma WES"
Research Agent → paperExtractUrls(Guo 2014) → Code Discovery → paperFindGithubRepo → githubRepoInspect → researcher gets curated repos with somatic mutation callers and BAP1 variant frequency notebooks.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(50+ BAP1 mesothelioma hits) → citationGraph → GRADE all → structured report on mutation prevalence. DeepScan applies 7-step CoVe to verify Testa (2011) pedigrees against modern cohorts. Theorizer generates hypotheses linking BAP1-HDACi from Carbone (2019) abstracts.
Frequently Asked Questions
What defines BAP1 germline predisposition to mesothelioma?
Germline BAP1 mutations cause familial mesothelioma with incomplete penetrance, often triggered by asbestos, as identified in Testa et al. (2011) via exome sequencing of 26 families.
How does BAP1 mutation affect mesothelioma survival?
BAP1 germline cases show 7-fold longer survival than wild-type, linked to slower progression (Baumann et al., 2014, n=43 patients).
Which are the key papers on BAP1 in mesothelioma?
Testa et al. (2011, 1060 citations) discovered germline link; Guo et al. (2014, 312 citations) found somatic frequency; Cigognetti et al. (2015, 298 citations) validated IHC.
What open problems exist in BAP1-mesothelioma research?
Therapy targeting BAP1 loss lacks trials; germline screening protocols absent from guidelines (Baas et al., 2015); functional rescue mechanisms unclarified (Sekido, 2013).
Research Occupational and environmental lung diseases with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching BAP1 Tumor Suppressor in Mesothelioma with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers